The lipid-lowering field is evolving at an ever-accelerating rate. With new studies at nearly every major meeting, clinicians need succinct summaries of the latest evidence and how to apply it in their practice.
Boston, MA (PRWEB)
March 22, 2017
High cholesterol — particularly a high level of low-density lipoprotein cholesterol (LDL-C) — is a main risk factor for developing cardiovascular disease (CVD), the number one cause of death in the United States. Treatment with statins has been shown to effectively lower LDL-C, but not for everyone. About 70% of patients with elevated LDL-C levels go untreated due to statin resistance, statin intolerance, familial hypercholesterolemia not well controlled on statins and nonadherence to statin treatment. For these patients, a newer class of injectable drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, represents one of the most promising strategies.
To help educate clinicians on PCSK9 inhibitors and CVD risk reduction, the National Lipid Association and PlatformQ Health are partnering to produce a two-part online series airing on CardioCareLive.com.
Part 1 – The Emerging Role of PCSK9 Inhibitors and CV Risk Reduction
Live: Tuesday, April 11, 2017 2:00 PM – 3:00 PM EST
Part 2 – CVD and PCSK9 Inhibitors: Analyzing the Outcome Studies and Understanding Their Implications
Live: Tuesday, May 23, 2017 11:00 AM – 12:00 PM EST
CME credit provided by the National Lipid Association.
These activities have been approved for AMA PRA CATEGORY 1 CREDIT™.
These activities are eligible for ACPE and ANCC credit.
- Michael J. Blaha, MD, MPH; Director of Clinical Research,…